ReviewJournal of translational medicine2026
Low oxygen preconditioning of umbilical cord MSCs: from biological to mechanistic innovation.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUmbilical cord-derived mesenchymal stem cells (UC-MSCs) represent a highly promising resource for regenerative medicine due to their potent immunomodulatory and proliferative capabilities, low immunogenicity, and ease of non-invasive collection. However, the low-oxygen (hypoxic) conditions these cells naturally experience are not adequately reproduced in standard in vitro culture systems. MAIN BODY: This review explores the impact of hypoxic preconditioning on UC-MSCs, with a particular focus on how reduced oxygen levels influence their biological traits and enhance their therapeutic potential. It also covers various methods for inducing hypoxia in vitro, including hypoxic chambers, chemical mimetics, three-dimensional culture systems, and also discusses physiological oxygen gradients and molecular pathways, notably hypoxia-inducible factors (HIFs). Evidence shows that hypoxic preconditioning improves UC-MSCs’ differentiation capacity, anti-inflammatory functions, survival, and resilience to oxidative stress.
conclusionsCollectively, these findings support the incorporation of hypoxic preconditioning into UC-MSC manufacturing and processing protocols to maximize their therapeutic efficacy and translational potential in regenerative medicine and cell-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.